Handelsavisen
prelaunch
Companies Healthcare 0557.HK
05
0557.HK HKEX Healthcare Facilities & Services

0557.Hk

HK$0,68
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
271,3M HKD
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
0,24
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the healthcare sector, specifically in the provision of healthcare facilities and services, and is engaged in the pharmaceuticals activity.

Business. The company operates in the healthcare sector, specifically in the provision of healthcare facilities and services, and is engaged in the pharmaceuticals activity.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 0557.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 0557.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare sector, specifically in the provision of healthcare facilities and services, and is engaged in the pharmaceuticals activity.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.24, indicating a relatively low level of leverage compared to the industry median. The liquidity position is marked by cash and equivalents of 27,733,000 HKD, which is partially offset by long-term debt of 38,716,000 HKD, resulting in a net cash position that is negative. The market capitalization of 183,530,581.04 HKD suggests a modest valuation relative to its revenue of 19,178,000 HKD, with an enterprise value to revenue ratio of 10.14.

    Profitability metrics are not explicitly provided, but the company's revenue of 19,178,000 HKD and the industry's preferred metrics suggest a need for further analysis to determine its performance relative to the cohort median. The company's earnings per share of 0.13 HKD and the reported revenue of 65,270,000 HKD for the last actual period indicate a potential for growth.

    The company's segments and geographic exposure are not detailed in the provided data, but the revenue concentration and the nature of the business suggest that it may be focused on a specific market or region. The lack of detailed segment information limits the ability to assess the diversification of its revenue streams.

    The growth trajectory of the company is not explicitly outlined, but the current financial performance and the industry outlook suggest that the company may be in a phase of moderate growth. The revenue history and the analyst estimates indicate a stable performance, with the potential for future expansion.

    The risk assessment of the company highlights a medium liquidity risk and a low dilution risk. The key flag of a negative net cash position after subtracting total debt suggests that the company may need to manage its liquidity carefully. The dilution potential is low, and no adjustments have been applied to the valuation metrics.

    Recent events and filings have not been detailed in the provided data, but the company's financial snapshot and valuation metrics suggest that it has maintained a stable financial position. The absence of recent events does not necessarily indicate a lack of activity, but rather a lack of disclosed information.

    Key takeaways
    • The company has a relatively low debt-to-equity ratio, indicating a conservative capital structure.
    • The enterprise value to revenue ratio of 10.14 suggests a modest valuation relative to its revenue.
    • The company's liquidity position is marked by a negative net cash position after subtracting total debt.
    • The company's earnings per share and revenue figures indicate a stable financial performance.
    • The risk assessment indicates a medium liquidity risk and a low dilution risk.
    • The company's growth trajectory is not explicitly outlined, but the financial performance suggests a potential for moderate growth.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$0,68
    Market cap
    HK$183.5M
    Enterprise value
    HK$194.5M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    -HK$11.0M
    Current ratio
    Debt / equity
    0.2
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    D/E0,24Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Enterprise Value
      market_cap - net_cash
    Source documents
    • 0557.HK Market data — financials · 2026-05-26
    • China Tian Yuan Healthcare Group Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    0557.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage